TWI740964B - 促進脂肪細胞分化之用途及篩選促進脂肪細胞分化物質之方法 - Google Patents
促進脂肪細胞分化之用途及篩選促進脂肪細胞分化物質之方法 Download PDFInfo
- Publication number
- TWI740964B TWI740964B TW106119776A TW106119776A TWI740964B TW I740964 B TWI740964 B TW I740964B TW 106119776 A TW106119776 A TW 106119776A TW 106119776 A TW106119776 A TW 106119776A TW I740964 B TWI740964 B TW I740964B
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- adipocytes
- srbc
- skin
- test substance
- Prior art date
Links
- 210000001789 adipocyte Anatomy 0.000 title claims abstract description 76
- 230000004069 differentiation Effects 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000012216 screening Methods 0.000 title claims abstract description 13
- 230000001737 promoting effect Effects 0.000 title claims abstract description 10
- 239000000463 material Substances 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 claims abstract description 65
- 238000012360 testing method Methods 0.000 claims abstract description 28
- 230000014509 gene expression Effects 0.000 claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 239000000126 substance Substances 0.000 claims description 53
- 238000002360 preparation method Methods 0.000 claims description 11
- 108050005259 Caveolae-associated protein 2 Proteins 0.000 claims description 6
- 102100032231 Caveolae-associated protein 2 Human genes 0.000 claims description 6
- 101710119301 Protein delta homolog 1 Proteins 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 102100036467 Protein delta homolog 1 Human genes 0.000 claims description 3
- 230000033001 locomotion Effects 0.000 claims description 2
- 230000037394 skin elasticity Effects 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 12
- 231100000241 scar Toxicity 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 38
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- -1 cleansing Substances 0.000 description 14
- 239000002537 cosmetic Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 9
- 239000006071 cream Substances 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102000000536 PPAR gamma Human genes 0.000 description 5
- 108010016731 PPAR gamma Proteins 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 4
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 230000003796 beauty Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 210000004003 subcutaneous fat Anatomy 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- YFOURACIUPVFFK-UHFFFAOYSA-N 2-[hydroxy-(6-oxo-3,7-dihydropurin-2-yl)amino]acetic acid Chemical compound O=C1NC(N(CC(O)=O)O)=NC2=C1NC=N2 YFOURACIUPVFFK-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 108050007101 Caveolae-associated protein 3 Proteins 0.000 description 1
- 102100024937 Caveolae-associated protein 3 Human genes 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010087894 Fatty acid desaturases Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- AEDMQUAPBVOJNN-UHFFFAOYSA-N [3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound O1C(CO)=NC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 AEDMQUAPBVOJNN-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000003863 ammonium salts Chemical group 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000010000 carbonizing Methods 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cosmetics (AREA)
Abstract
本發明揭露包括作為活性成分之促進SRBC表現之物質之組成物及篩選促進脂肪細胞分化物質之方法。包括本發明一態樣之作為活性成分之促進SRBC表現物質之該組成物能促進脂肪細胞分化,因此可有用地應用於皮膚護理、疤痕治療等。此外,本發明一態樣之該篩選促進脂肪細胞分化物質之方法允許利用一測試物質治療皮膚脂肪細胞及鑑別SRBC基因之相對表現程度,從而可方便、快捷及有效地篩選出能促進脂肪細胞分化之物質。
Description
本發明揭露作為活性成分之包括促進SRBC表現或活性物質之組成物及篩選促進脂肪細胞分化物質之方法。
皮膚之基本結構係藉由皮下脂肪組織維持,而皮下脂肪組織影響皮膚之容積及強度。因此,相較於對外皮膚層中之真皮層或表皮層提供彈性,增加皮下脂肪容積更能維持皮膚之容積及彈性。同時,為了增加脂肪組織之容積,正在對用於促進脂肪細胞分化之物質進行研究。該術語「脂肪細胞分化(differentiation of adipocytes)」係指前脂肪細胞(preadipocytes)被轉換成脂肪細胞之中我們身體在生命週期中持續發生之一系列程序。據報導脂肪細胞分化係藉外部刺激(諸如激素)經由基因表現之複雜調控過程於細胞內發生。在誘導脂肪細胞分化之外部信號之中,胰島素係最廣為人知之激素且已知在脂肪細胞代謝調控中有關鍵作用。
[技術問題]
在一態樣中,本發明目的在於提供一新穎脂肪細胞分化標誌(adipocyte differentiation marker)。
在另一態樣中,本發明目的在於促進脂肪細胞分化及藉此增進皮膚容積。
在另一態樣中,本發明目的在於使用一新穎標誌以便利方法篩選促進脂肪細胞分化之物質。
[技術方案]
在一態樣中,本發明提供一組成物,其包括作為活性成分之能促進與C-激酶結合之血清剝奪反應因子相關之基因產物(Serum deprivation Response factor-related gene product that Binds to C-kinase,SRBC)表現或活性之物質。
在另一態樣中,本發明提供一護膚方法,其包括以一組成物處理皮膚之步驟,該組成物包括作為活性成分之能促進SRBC表現或活性之物質。
在另一態樣中,本發明提供脂肪細胞分化之方法,其包括以一組成物處理分離之脂肪細胞之方法,該組成物包括作為活性成分之能促進SRBC表現或活性之物質。
且,在另一態樣中,本發明提供一篩選促進脂肪細胞分化物質之方法,其包括以下步驟:以一測試物質處理脂肪細胞;及在經該測試物質處理之脂肪細胞中判斷以該測試物質處理前後之 與C-激酶結合之血清剝奪反應因子相關之基因產物(SRBC)表現程度。
在另一態樣中,本發明提供一篩選能促進脂肪細胞分化物質之套組,其包括一脂肪細胞;及說明書,其中該說明書描述該方法。
[發明效果]
包括本發明一態樣之作為活性成分之能促進SRBC表現或活性之組成物能促進脂肪細胞分化且因此可有用地應用於護膚、疤痕治療等。此外,本發明一態樣之篩選促進脂肪細胞分化物質之方法允許以一測試物質處理脂肪細胞及判斷SRBC基因相對表現程度,從而能方便、快速及有效地篩選促進脂肪細胞分化之物質。
本文以下,本發明將被詳述。
在一態樣中,本發明係一促進脂肪細胞分化之組成物,其包括一作為活性成分之能促進 與C-激酶結合之血清剝奪反應因子相關之基因產物(SRBC)表現或活性之物質。
此外,在一態樣中,本發明係一增進皮膚容積之組成物,其包括一作為活性成分之促進SRBC表現或活性之物質。
此外,在一態樣中,本發明係一改善皮膚皺紋或增進皮膚彈性之組成物,其包括一作為活性成分之促進SRBC表現或活性之物質。
SRBC表現及脂肪細胞分化間之關係仍未知。本案發明人首次發現SRBC係脂肪細胞分化之標誌,其係藉由發現當SRBC表現量增加時,已知與脂肪細胞分化有關之 過氧化物酶體增殖物活化受體γ(peroxisome proliferator-activated receptor gamma,PPAR-γ)及脂肪酸合成酶(fatty acid synthase ,FAS)之表現被向上調控且三酸甘油酯增加。
本文使用之術語「皮膚」係指一器官,其覆在活生物體之外側及由表皮層、真皮層及皮下脂肪層組成。該術語不僅包括為覆在臉部或全身外側之組織而且包括頭皮及頭髮。
本文使用之術語「容積(volume)」係指皮膚層表面或内部之容積或容量。此可能意指表面膨大(voluminous)之外觀。據此,具增加或增進容積之皮膚看起來緊伸(lifted)、健康且年輕。且,舉例而言,當皮膚損傷(injury)、創傷(wound)、燒傷等而受損及因其造成之疤痕或凹陷或皮膚或組織因手術被切開等,皮膚組織容積之增進可致使受傷組織及皮膚層容積增加且提供皮膚或組織恢復成近似其原本狀態之效果。
本文使用之術語「容積增進(enhancement of volume)」係指皮膚層容積增加。其亦指緊伸(lifted)及健康外觀之皮膚或受傷皮膚組織因皮膚容積增加而恢復成近似其原本狀態。據此,增加皮膚組織容積可提供受傷皮膚因下垂(drooping)皮膚之容積增加及皮膚表面拉緊(stretched)而被恢復成近似其原本狀態之效果。
在以上態樣中,該組成物可抑制 前脂肪細胞因子-1 (preadipocyte factor-1,pref-1)移動至細胞核中。此外,該組成物可抑制pref-1之表現。
在以上態樣中,該組成物可增加一或多選自於由過氧化物酶體增殖物活化受體γ(PPARγ)、脂肪酸合成酶(FAS)、硬脂醯基-CoA去飽和酶1 (stearoyl-CoA desaturase 1,SCD-1)及脂聯素(adiponectin)所組成之群組之表現。
在一具體實施例中,該組成物可包括一載體(vector),其包括一基因編碼SRBC。於此態樣中,該基因可包括基因ID: 109042之序列。在一具體實施例中,該載體可為pcDNA 3.1 載體(Invitrogen Co., Carlsbad, CA, USA),其中一基因編碼SRBC係被***在Xba
I位及Bam
HI位之間。SRBC之基因序列可由Pubmed之基因ID: 109042取得。
在以上態樣中,該組成物可包括以該組成物總重量為基礎0.0001至70 wt%之用以促進SRBC表現或活性之物質。舉例而言,其可為不少於0.0001 wt%、不少於0.01 wt%、不少於0.1 wt%、不少於10 wt%、不少於20 wt%、不少於30 wt%、不少於40 wt%、不少於50 wt%、或不少於60 wt%且不多於70 wt%、不多於60 wt%、不多於50 wt%、不多於40 wt%、不多於30 wt%、不多於20 wt%、不多於10 wt%、不多於1wt%、不多於0.1 wt%或不多於0.001 wt%。
在一具體實施例中,該組成物可為用於皮膚護理之組成物。用於皮膚護理之該組成物可為一美容組成物。
在一具體實施例中,該組成物可為用於恢復凹陷(depressed)皮膚之一藥學組成物。
該美容組成物可為,舉例而言,基礎美容品(basic cosmetics)、化妝美容品(makeup cosmetics)、護髮美容品(hair care cosmetics)、美體美容品(body care cosmetics)等。其配方未受特別限制且可適當地依照目前而被選擇。
舉例而言,該美容組成物可配製為以下但不限於此:溶液(solution)、懸浮液(suspension)、乳劑(emulsion)、糊劑(paste)、膠劑(gel)、乳霜(cream)、洗劑(lotion)、粉末(powder)、肥皂(soap)、含表面活性劑之清潔劑(cleansing)、油(oil)、粉底(powder foundation)、粉底液(emulsion foundation)、粉底蠟(wax foundation)、噴劑(spray)等。更具體地,其可被配製成:基礎美容物,諸如軟化水(softening lotion)、滋養液(nourishing lotion)、乳液(milk lotion)、美體液(body lotion)、滋養霜(nourishing cream)、按摩霜(massage cream)、保濕霜(moisturizing cream)、護手霜(hand cream)、精華液(essence)、眼霜(eye cream)、潔膚霜(cleansing cream)、潔膚泡沫(cleansing foam)、潔膚水(cleansing water)、面膜(pack)、膠劑、貼片(patch)、水包油(O/W)乳劑、油包水(W/O)乳劑等;彩妝美容物(coloring cosmetics),諸如唇膏(lipstick)、妝前打底(makeup base)、粉底(foundation)等;清潔品,諸如洗髮精、潤絲精、沐浴精(body cleanser)、牙膏、漱口水(mouthwash)等;或護髮美容品,諸如養髮液(hair tonic)、諸如髮膠或慕斯之髮用定型劑(hair fixatives)、生髮劑(hair growth promoter)、染髮劑(hairdye)等。
該美容組成物包含美容上可接受之介質(medium)或基質(matrix)。這可以以任何適用之配方提供,例如:溶液,膠劑,無水固體或糊劑,水包油乳劑,懸浮液,微乳劑(microemulsion),微膠囊,微粒(microgranule)或離子(脂質體)及/或非離子型囊分散體(nonionic vesicular dispersion),霜劑,皮膚洗劑,乳液,粉末,軟膏(ointment),噴霧劑或隱形棒(conceal stick)。此等組成物可依照本領域中常用方法製備。
當本發明之配製物係溶液或乳劑,可使用溶劑、溶解劑或乳化劑(emulsifier)作為載劑(carrier)。其實例包括水、乙醇(ethanol)、異丙醇(isopropanol)、碳酸乙酯(ethyl carbonate)、乙酸乙酯(ethyl acetate)、苯甲醇(benzyl alcohol)、苯甲酸芐酯(benzyl benzoate)、丙二醇(propylene glycol)、1,3-丁二醇油(1,3-butyl glycol oil)、甘油脂肪酯(glycerol aliphatic ester)、聚乙二醇(polyethylene glycol)或脫水山梨醇脂肪酸酯(fatty acid ester of sorbitan)。
當本發明之配製物係懸浮液,可使用液體稀釋劑(諸如水、乙醇或丙二醇)、懸浮劑(諸如乙氧基化異硬脂醇(ethoxylated isostearyl alcohol)、聚氧乙烯山梨醇酯(polyoxyethylene sorbitol ester)及聚氧乙烯山梨糖醇酯(polyoxyethylene sorbitan ester))、微晶纖維素(microcrystalline cellulose)、偏氫氧化鋁(aluminum metahydroxide)、膨潤土(bentonite)、瓊脂(agar)或黃蓍膠(tragacanth)等作為載劑。
當本發明之配製物係糊劑,可使用霜劑或膠劑、動物油、植物油、蠟、石蠟、澱粉、黃蓍膠(tragacanth)、纖維素衍生物、聚乙二醇、矽氧烷(silicone)、膨潤土、二氧化矽(silica)、滑石或氧化鋅等作為載劑。
當本發明之配製物係粉末或噴霧劑,可使用乳糖、滑石、二氧化矽、氫氧化鋁、矽酸鈣或聚醯胺粉末作為載劑。特別地,當該配製物為噴霧劑,其可進一步包括推進劑,諸如氯氟烴(chlorofluorohydrocarbon)、丙烷/丁烷或二甲醚。
本發明之一具體實施例,該美容組成物可進一步含有增稠劑。該包含在本發明美容組成物中之增稠劑可為甲基纖維素(methyl cellulose)、羧甲基纖維素(carboxymethyl cellulose)、羧甲基羥基鳥嘌呤(carboxymethyl hydroxyguanine)、羥甲基纖維素(hydroxymethyl cellulose)、羥乙基纖維素(hydroxyethyl cellulose)、羧基乙烯基聚合物(carboxyvinyl polymer)、聚季銨鹽(polyquaternium)、鯨蠟硬脂醇(cetearyl alcohol)、硬脂酸(stearic acid)、鹿角菜膠(carrageenan)等。較佳地,可使用羧甲基纖維素、羧基乙烯基聚合物及聚季銨鹽之一或多者。最佳地,可使用羧基乙烯基聚合物。
本發明之一具體實施例,該美容組成物可根據需要包含各種適當之基質及添加劑,且其類型及數量可由本領域技術人員容易地確定。該美容組成物可根據需要包含可接受之添加劑。舉例而言,其可包含有本領域通常使用之防腐劑、著色劑、添加劑等。
具體而言,防腐劑可為苯氧基乙醇(phenoxyethanol)、1,2-己二醇(1,2-hexanediol)等,且可使用合成香料。
此外,本發明之一具體實施例中,該美容組成物可包括一組成物,其係選自於由以下所組成之群組:水溶性維生素、油溶性維生素、多肽類(polypeptide)、多醣類(polysaccharide)、神經鞘脂(sphingolipid)及海藻萃取物。此外,其可進一步包括油及脂肪、潤濕劑(humectant)、潤滑劑(emollient)、表面活性劑、有機或無機顏料、有機粉末、紫外線吸收劑、防腐劑、滅菌劑(sterilizer)、抗氧化劑、植物萃取物、pH調節劑、乙醇、著色劑、香料、血液循環興奮劑、冷卻劑、止汗劑、淨化水等。
然而,可包含在該美容組成物中之成分不限於此。且,該等成分之數量可在不對本發明目的及效果產生不利影響之範圍內被確定。
本發明一態樣之藥學組成物可為各種口服或非經腸胃之配製物。當該組成物被配製,使用常用之稀釋劑或賦形劑,諸如填料、增量劑、黏合劑、濕潤劑、崩解劑、表面活性劑等。用於口服之固體製劑包含片劑(tablets)、丸劑(pills)、粉劑(powders)、顆粒劑(granules)、軟膠囊或硬膠囊劑(soft or hard capsules)等,及藉由將至少一化合物與至少一賦形劑混合來製備,該賦形劑例如澱粉、碳酸鈣、蔗糖或乳糖、明膠等。此外,除了單純賦形劑外,可使用諸如硬脂酸鎂、滑石等之潤滑劑。用於口服之液體製劑包含懸浮液、溶液、乳劑、糖漿等,及可加入各種賦形劑(諸如濕潤劑、甜味劑、調味劑、防腐劑)以及常用作為單純稀釋劑之水及液體石蠟。非經腸胃給藥之製劑包括無菌水溶液、非水溶劑、懸浮液、乳劑、冷凍乾燥製劑及栓劑。可使用丙二醇、聚乙二醇、植物油(如橄欖油)、注射型酯(如油酸乙酯)等作為非水溶劑或懸浮液。可使用維太素(witepsol)、聚乙烯二醇(macrogol)、吐溫61(tween 61)、可可脂(cacao butter)、梓(laurinum)、甘油明膠(glycerogelatin)等作為栓劑基質。
在本發明之一態樣中,該組成物可依據目的非經腸胃或口服給藥。其可依一至數個分割劑量以使得每日劑量為每公斤體重0.1-500 mg,較佳為1-100 mg。給病患之劑量可依據該病患之體重、年齡、性別、健康狀況、飲食、施用次數、施用方法、排出率、疾病嚴重程度等來改變。
本發明一態樣之藥學組成物可被配製成任何適合用於藥學製劑之形式,其包含口服製劑(諸如粉末、顆粒、片劑、軟或硬膠囊劑、懸浮液、乳劑、糖漿)及氣溶膠、注射劑及無菌注射溶液。
本發明一態樣之組成物可經由各種途徑(諸如非經腸胃、口服等)施予哺乳動物(諸如大鼠、小鼠、家畜及人類等),且所有施藥方法皆可預測。舉例而言,其可經口、經皮、靜脈內、肌肉內或經由皮下注射施予。
本發明一態樣之健康食品組成物製劑未被特別限制,但該組成物可被配製成例如液體製劑(諸如片劑、顆粒、粉末及飲品(drinks)、焦糖(caramels)、膠體(gels)、棒狀物(bars)等。本發明之食品組成物可包括各種營養品、維生素、礦物質(電解質)、調味劑(諸如合成調味劑及天然調味劑)、著色劑及改善劑(乳酪、巧克力等)、果膠酸及其鹽類、藻酸及其鹽類、有機酸、保護性膠體增稠劑(protective colloidal thickening agent)、pH調控劑、穩定劑、防腐劑、甘油、乙醇、用於碳酸飲料中之碳酸化劑(carbonizing agent)等。在各製劑之食品組成物中,除該活性成分外,本領域技術人士可以依據該組成物配製目的毫無困難地適當選擇及添加其他常用成分。添加其他成分,特別為含益生菌之組成物可,可能會產生協同效應。
在另一態樣中,本發明係一護膚方法,其包括以該組成物處理皮膚。在一具體實施例中,該組成物可經皮施予至有皺紋之皮膚、有疤之皮膚等,以達到護膚效果。
在另一態樣中,本發明係用於脂肪細胞分化之方法,其包括以該組成物處理分離脂肪細胞之步驟。在一具體實施例中,脂肪細胞係由一需要護膚之受試者(即供給者)分離,該經分離之脂肪細胞係經促進SRBC表現或活性之物質處理以分化脂肪細胞,然後該經分化之脂肪細胞係被施予該供給者。於此情況中,因為使用受試者自己之細胞,故可去除疤痕而不會有諸如免疫反應等副作用之優點。
在另一態樣中,本發明提供一篩選促進脂肪細胞分化物質之方法,其包括以下步驟:以一測試物質處理脂肪細胞;及在經該測試物質處理之脂肪細胞中判斷以該測試物質處理前後SRBC表現程度。
本文使用之術語「相對表現程度」係指相較於未經一測試物質處理之脂肪細胞中SRBC表現程度之經該測試物質處理之脂肪細胞中SRBC表現程度。該表現程度可能涵蓋表現之數量及表現之性質。此外,該表現程度可能涵蓋例如蛋白質之表現程度。
在以上態樣中,該方法可能進一步包括以下步驟:當經一測試物質處理後之脂肪細胞中SRBC表現程度高於經該測試物質處理前之脂肪細胞中SRBC表現程度時,確定該測試物質為促進脂肪細胞分化或增進皮膚容積之物質。舉例而言,經一測試物質處理之脂肪細胞中之SRBC表現程度高於未經該測試物質處理之脂肪細胞中之SRBC表現程度,可確定所施用之測試物質會增加SRBC表現程度。如上所述,若一施用之測試物質增加SRBC表現程度,可確定其為促進脂肪細胞分化之物質。
在一具體實施例中,可依已知技術判斷SRBC基因表現程度,例如但不限於反轉錄聚合酶連鎖反應(reverse transcription polymerase chain reaction ,RT-PCR)、酵素免疫分析法(ELISA)、西方轉漬法(western blotting)或免疫轉漬法(immune blotting)。
在一具體實施例中,在判斷一測試物質為促進脂肪細胞分化或增進皮膚容積之物質之步驟中,當在經該測試物質處理後該脂肪細胞中SRBC表現程度為至少1.1倍高於在經該測試物質處理前該脂肪細胞中SRBC表現程度,該測試物質可被判斷為促進脂肪細胞分化或增進皮膚容積之物質。在以一測試物質處理後該脂肪細胞中SRBC表現程度可為例如但不限於至少1.1倍、至少1.2倍、至少1.3倍、至少1.4倍、至少1.5倍、至少1.6倍、至少1.7倍、至少1.8倍、至少1.9倍、或至少2倍高於以該測試物質處理前者。 該表現程度係具統計顯著性之測量結果。該術語「具統計顯著性」係指根據生物統計學存在顯著性差異之情況,其包含在定量分析中p值小於0.05之情況。在另一態樣中,本發明係一用於篩檢促進脂肪細胞分化物質之套組,其包括脂肪細胞及說明書,其中該說明書描述該方法。
本文以下將參照實施例更詳細地描述本發明之組成和效果。然而,以下之實施例僅用於說明目的,本發明範圍不以任何方式受限於該等實施例。
[實施例] [實施例1] 製備SRBC-過度表現細胞株 [實施例1-1] 細胞培養 使用6孔盤於5% CO2
培養箱中在含10%小牛血清(Gibco BRL, NY, USA)及5%青黴素鏈黴素之Dulbecco改良Eagle培養基(Dulbecco's modified Eagle's medium,DMEM) (Lonza, MD, USA)中培養小鼠3T3-L1纖維母細胞(ATCC, CL-173)2天,使其增殖而不分化。
[實施例1-2] 細胞分化 在實施例1-1中,在6孔盤中培養該未分化之脂肪細胞至95%匯集度(confluence)。然後,在5% CO2
培養箱中在含10%胎牛血清(fetal bovine serum,FBS)(PAA, Austria)、 10 μg/ml胰島素(Sigma- Aldrich, St. Louis, USA)、0.5 mM 3-異丁基-1-甲基黄嘌呤(3-isobutyl-1-methylxantine,IBMX) (Sigma-Aldrich, St. Louis, USA)及1 μM***(dexamethasone,DEX) (Sigma-Aldrich, St. Louis, USA)之DMEM中培養2天。此後,在補充10%FBS及10 μg/ml胰島素之DMEM中培養另3天。然後,在含10%FBS之DMEM中只培養該等細胞2天以獲得分化之脂肪細胞。
[實施例1-3] RNA萃取及cDNA合成 使用TRIzol (Gibco BRL, NY, USA)萃取RNA及使用反轉錄系統(Reverse Transcription System)(Promega Co, WI, USA)合成cDNA。
[實施例1-4] 即時定量RT-PCR (RT-qPCR) TaqMan®探針(Life technologies, CA, USA)及master mix (Life technologies, CA, USA)係被加入至實施例1-3中合成之cDNA,各基因之表現係使用Rotor-gene 3000 (Corbett Research, AUS)來分析。
[實施例1-5] 產生過度表現之細胞株 SRBC cDNA在實施例1-1培養之小鼠纖維母細胞中被合成,其使用引子(primer) (5'-GGAATTCCAATGGGGGAGAGC-3', 5'-GGGTACCGGCTGCGCTCTCTAT-3')。該被合成之cDNA被***pcDNA3.1載體(Invitrogen Co., Carlsbad, CA, USA) XbaI及BamHI之間以轉染小鼠3T3-L1纖維母細胞。然後該被轉染之細胞經以含嘌黴素(puromycin)之培養基(3 μg/ml)選擇。
[實施例2]過度表現細胞株之油紅O染(Oil Red O Staining)及成像 製備油紅O(Oil Red O,ORO)(Sigma-Aldrich, St. Louis, USA)溶解在60%丙二醇(propylene glycol,PG) (Santa Cruz Biotechnology, Inc., CA, USA)之原液(stock solution)以判斷小鼠中分化纖維母細胞三酸甘油酯(triacylglycerol,TG)之數量。由實施例1及2獲得未分化細胞及各分化階段之細胞,以冷磷酸鹽緩衝液(phosphate-buffered saline,PBS) (Welgene, Daegu, Korea)沖洗兩次然後以3.7%甲醛(Sigma-Aldrich, St. Louis, USA)固定1小時。然後,以冷PBS沖洗該細胞兩次及以預製備好之ORO原液染色30分鐘。以流動水沖洗之後,以Olympus IX71 (Tokyo, Japan)成像該經染色之細胞。成像後,以100% PG溶解ORO及於450 nm測量吸收度以量化TG量。
結果顯示當SRBC過度表現時,脂肪細胞會以相較於正常情況快之速率分化(圖1及2)。
本發明對具體實施例進行描述,對本領域技術人而言顯然地可進行各種改變及修飾而不會悖離所附申請專利範圍定義之本發明精神及範圍之情況下。
圖1顯示正常細胞及SRBC過度表現細胞間之差異,其係以脂肪細胞分化相關因子表現之變化為基礎。
圖2顯示使用油紅O脂染(Oil Red O fat staining)裸視正常細胞及SRBC過度表現細胞間差異之觀察結果。
圖3顯示當SRBC被過度表現時測量被合成三酸甘油酯(triacylglycerol,TG)之結果。
<110> 南韓商愛茉莉太平洋股份有限公司
<120> 促進脂肪細胞分化之用途及篩選促進脂肪細胞分化物質之方法
<140> 106119776
<141> 2017-06-14
<150> KR 10-2016-0081790
<151> 2016-06-29
<150> KR 10-2017-0072314
<151> 2017-06-09
<160> 2
<210> 1
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 引子
<210> 2
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 引子
Claims (12)
- 一種利用包括一與C-激酶結合之血清剝奪反應因子相關之基因產物(SRBC)基因編碼的載體作為用於製備一促進脂肪細胞分化之組成物的用途。
- 一種利用包括一與C-激酶結合之血清剝奪反應因子相關之基因產物(SRBC)基因編碼的載體作為用於製備一增進皮膚容積之組成物的用途。
- 一種利用包括一與C-激酶結合之血清剝奪反應因子相關之基因產物(SRBC)基因編碼的載體作為用於製備一改善皮膚皺紋或增近皮膚彈性之組成物的用途。
- 如請求項1至3任一者所述之用途,其中該組成物抑制前脂肪細胞因子-1(pref-1)移動至細胞核或抑制其表現。
- 如請求項1至3任一者所述之用途,其中該組成物係一護膚組成物。
- 如請求項1或2所述之用途,其中該組成物係一用於恢復凹陷皮膚之藥學組成物。
- 如請求項1至3任一者所述之用途,其中該組成物包括以該組成物總重量為基礎0.0001至70wt%之包含該SRBC基因編碼的載體。
- 一種用於脂肪細胞分化之方法,其包括以請求項1至3任一者所述之組成物處理分離脂肪細胞之步驟。
- 一種篩選促進脂肪細胞分化物質之方法,其包括以下步驟: 以一測試物質處理脂肪細胞;及在以該測試物質處理前後判斷以該測試物質處理之該脂肪細胞中與C-激酶結合之血清剝奪反應因子相關之基因產物(SRBC)相對表現程度。
- 如請求項9所述之方法,其中該方法進一步包括一步驟,當經該測試物質處理後該脂肪細胞中之SRBC表現程度高於經該測試物質處理前該脂肪細胞中之SRBC表現程度,確定該測試物質為促進脂肪細胞分化或增進皮膚容積之物質。
- 如請求項10所述之方法,其中在確認該測試物質為促進脂肪細胞分化或增進皮膚容積之物質之步驟中,當以該測試物質處理後該脂肪細胞中之SRBC表現程度至少為1.1倍高於以該測試物質處理前該脂肪細胞中之SRBC表現程度,該測試物質被確定為促進脂肪細胞分化或增進皮膚容積之物質。
- 一種用於篩選用於促進脂肪細胞分化物質之套組,其包括脂肪細胞;及說明書,其中該說明書描述請求項9至11任一者所述之方法。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0081790 | 2016-06-29 | ||
??10-2016-0081790 | 2016-06-29 | ||
KR20160081790 | 2016-06-29 | ||
??10-2017-0072314 | 2017-06-09 | ||
KR1020170072314A KR102359441B1 (ko) | 2016-06-29 | 2017-06-09 | 지방세포 분화 촉진용 조성물 및 지방세포 분화 촉진 물질의 스크리닝 방법 |
KR10-2017-0072314 | 2017-06-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201800088A TW201800088A (zh) | 2018-01-01 |
TWI740964B true TWI740964B (zh) | 2021-10-01 |
Family
ID=60785457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106119776A TWI740964B (zh) | 2016-06-29 | 2017-06-14 | 促進脂肪細胞分化之用途及篩選促進脂肪細胞分化物質之方法 |
Country Status (2)
Country | Link |
---|---|
TW (1) | TWI740964B (zh) |
WO (1) | WO2018004171A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI760704B (zh) | 2020-03-05 | 2022-04-11 | 優達生醫科技股份有限公司 | 血管評估天線裝置 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001092527A2 (en) * | 2000-06-01 | 2001-12-06 | Incyte Genomics, Inc. | Regulators of apoptosis |
DK2055308T3 (en) * | 2006-10-30 | 2017-07-17 | Genomix Co Ltd | PHARMACEUTICALS FOR PROMOTING FUNCTIONAL REGENERATION OF DAMAGED TISSUE |
-
2017
- 2017-06-14 TW TW106119776A patent/TWI740964B/zh active
- 2017-06-20 WO PCT/KR2017/006436 patent/WO2018004171A1/ko active Application Filing
Non-Patent Citations (2)
Title |
---|
Bastiani M, "MURC/Cavin-4 and cavin family members form tissue-specific caveolar complexes", J. Cell Biol. Vol., 185, No. 7, 2009, page 1259–1273. |
Mohan J, "Cavin3 interacts with cavin1 and caveolin1 to increase surface dynamics of caveolae", Journal of Cell Science, Vol. 128, No. 10, 2015, page 979–991. |
Also Published As
Publication number | Publication date |
---|---|
WO2018004171A1 (ko) | 2018-01-04 |
TW201800088A (zh) | 2018-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103479694B (zh) | 含有人参的花或人参的种子提取物的皮肤外用剂组合物 | |
CN103379911B (zh) | PGC-1α调节肽 | |
CN108379110B (zh) | 护肤组合物、护肤膏霜及其制备方法 | |
JP2010528090A (ja) | テンシン1発現を刺激することのできる活性薬剤を含む化粧用組成物 | |
JP2020528874A (ja) | 皮膚及び/又は粘膜を水和させるためのネフェリウム・ラパセウム(nephelium lappaceum)の果皮の抽出物の使用 | |
US20190111108A1 (en) | Composition Including GDF11 and Use Thereof | |
TWI747280B (zh) | 余甘子萃取發酵物及其製備與應用 | |
CN110693773A (zh) | 防脱发或毛发生长促进用组合物 | |
EP3097913B1 (en) | Cosmetic use of a hydroxypyranone derivative compound for promoting differentiation of adipocytes | |
JP2021080273A (ja) | ミノキシジルとペプチドの結合体 | |
EP2629753B1 (en) | Extracts of monodus sp. and their application | |
JPWO2018199231A1 (ja) | プラセンタ抽出物 | |
TWI740964B (zh) | 促進脂肪細胞分化之用途及篩選促進脂肪細胞分化物質之方法 | |
US20210283204A1 (en) | Lin28a ACTIVATOR AND USE THEREFOR | |
JP2003137768A (ja) | 抗老化剤 | |
EP4169502A1 (en) | Cosmetic and dermatological use of rubus fruticosus fruit extract | |
KR20190062173A (ko) | 프로테아제활성화수용체(par2)의 작용제를 포함하는 피부 주름 개선 또는 노화 방지용 화장료 조성물 | |
KR102359441B1 (ko) | 지방세포 분화 촉진용 조성물 및 지방세포 분화 촉진 물질의 스크리닝 방법 | |
JP2010168292A (ja) | 架橋コラーゲン類及び該コラーゲン類を含む化粧料 | |
CN105943414B (zh) | 包括野山参培养根油作为活性成分的化妆品组合物,其制备方法及使用其的化妆方法 | |
JP2023529466A (ja) | 抗肥満活性を有するデオキシコール酸-ペプチド結合体及びその用途 | |
US10406086B2 (en) | Moisturizer and cosmetic including the same | |
KR20220026103A (ko) | 헴프시드 추출물을 포함하는 두피 및 모발 상태 개선용 조성물 | |
KR101261731B1 (ko) | 콜라겐 생성 촉진용 피부 외용제 조성물 | |
JP3686394B2 (ja) | 抗老化剤、メイラード反応阻害剤、コラゲナーゼ活性阻害剤及びこれらを含有する皮膚老化防止用化粧料 |